TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00434876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Inactive or inert pill which will be used as a comparator.
Study: NCT02717819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Daily intake of supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
Study: NCT03530631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall
Description: Participants will be administered Adderall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall
Description: Participants will be administered Adderall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo
Study: NCT00880074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo fluorine F-18 fluorothymidine PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluorine F-18 fluorothymidine PET
Study: NCT01042184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy for 14 days
Description: D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
Study: NCT01042184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy for 10 days
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Study: NCT00613938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503)
Description: 75mg capsule q4-6 hrs for 3 days
Study: NCT01042184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy for 14 days
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study: NCT00613938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 10mg capsule q4-6 hrs for 3 days
Study: NCT02888821

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CLS-FUERTE
Description: The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
Study: NCT01633372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Study: NCT00810485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: oral administration
Study: NCT02888821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-FUERTE
Description: The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
Study: NCT00800176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 2.5mg po daily for 12 weeks
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
Study: NCT00800176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 5mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 10mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 40mg po daily for 12 weeks
Study: NCT01633372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Study: NCT04830904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized Lycra garments
Description: the subjects wear lycra garments during the assessment time and for some days after the assessment
Study: NCT00879593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PtcCO2
Description: Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
Study: NCT03887260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study: NCT01586286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment Base
Description: Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Study: NCT00613938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule q4-6 hrs for 3 days
Study: NCT03218033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Media
Study: NCT03134989

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear implant
Description: Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
Study: NCT04813094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based integrated-management Program
Description: The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
Study: NCT02177045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonovue, Bracco
Description: Intravenous injection
Study: NCT03486132

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of episiotomy
Description: Different techniques for repair of episiotomy incsicion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of episiotomy
Description: Different techniques for repair of episiotomy incsicion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of episiotomy
Description: Different techniques for repair of episiotomy incsicion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of episiotomy
Description: Different techniques for repair of episiotomy incsicion
Study: NCT02444689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Media Application
Description: Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care education
Study: NCT00640900

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
Study: NCT03887260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Regional anaesthesia technique performed under ultrasound guidance before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
Study: NCT00765882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 micrograms
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 micrograms
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study: NCT01887821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Study: NCT02727556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Study: NCT04246333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mode of Delivery of Feeds
Description: Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
Study: NCT02261129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan uncoated tablet
Study: NCT02919280

Intervention type: OTHER
Intervention: Observational Study
Description: The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
Study: NCT02943356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will be treated with Tadalafil for 8 weeks
Study: NCT03428438

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation at home via SMS
Description: Cardiac rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation at home via SMS
Description: Cardiac rehabilitation
Study: NCT01217099

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: methylprednisolone
Description: treatment patients were iv methylprednisolone pulse azithromycin for 5 days.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: azithromycin
Description: control patients were iv azithromycin for 5 days.
Study: NCT03951259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM934
Description: In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM934
Description: In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Study: NCT00640900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Description: Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Description: Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
Study: NCT02473380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence spectroscopy guided surgery
Description: A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
Study: NCT01691937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block with ropivacaine
Description: Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with sufentanil
Description: Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia with sufentanil
Description: Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral Block with Saline
Description: Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
Study: NCT00962416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus eluted from an erodable stent coating (Biomatrix)
Description: The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent (Gazelle)
Description: A bare-metal stent of identical design without surface application of polymer and drug.
Study: NCT03042663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USG stellate ganglion block
Description: After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
Study: NCT03951259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM934
Description: In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo pills are made identical to the investigating SM934 in appearance.
Study: NCT03717727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: 16-week home-based exercise intervention with exergaming system and usual treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 16-week home-based exercise by standard protocol and usual treatment.
Study: NCT03140033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranitidine Oral Tablet
Description: at cord clamping the patient will recieve ranitidine sublingually
Study: NCT01100203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
Study: NCT02365272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Amikacin administered in a single dose for critical care patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Amikacin administered in a single dose for critical care patients
Study: NCT01730625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for anxiety
Study: NCT03383848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Management Software
Description: The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days.
Study: NCT01728298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone ULTRA HDM immunotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone ULTRA HDM immunotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone ULTRA HDM immunotherapy
Study: NCT03365232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non custom base attachment
Description: non custom base attachment
Study: NCT01730625

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy for anxiety

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy for anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment